Clinical Trials on Hepatitis D, Chronic

Total 36268 results

AbbVie

Completed

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation (EVEREST)

Chronic Hepatitis C (CHC)

Russian Federation
Merck Sharp & Dohme LLC

Completed

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Chronic Hepatitis C Genotype 1
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Chronic Hepatitis C (CHC)
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs

Chronic Hepatitis C (Disorder)
King Abdulaziz Medical City

Completed

Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4

Chronic Hepatitis C Virus

Saudi Arabia
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
Hannover Medical School
German Center for Infection Research

Recruiting

Terminator 2 Register

Chronic Hepatitis B, HBeAg Negative

Germany
Janssen R&D Ireland

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients

Chronic Hepatitis C Infection

Taiwan
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie (prior sponsor, Abbott)

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States
Assiut University

Unknown

Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients

Chronic Hepatitis c

Egypt
Cairo University

Unknown

Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c

Chronic Hepatitis c

Egypt
MinaPharm Pharmaceuticals

Unknown

Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population (Quadritherapy)

Chronic Hepatitis c

Egypt
Cairo University
Egyptian Railway Hospital

Completed

Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)

Chronic Hepatitis c

Egypt
Ascletis Pharmaceuticals Co., Ltd.
Peking University First Hospital; Beijing Clinical Service Center

Active, not recruiting

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Chronic Hepatitis b

China
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis b

China
University of Nebraska

Withdrawn

Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C

Chronic Hepatitis C

United States
Korea University
Yonsei University; Inje University; The Catholic University of Korea; CHA University and other collaborators

Unknown

Tenofovir Combination or Mono-therapy for MDR CHB

Chronic Hepatitis b With Multidrug Resistance

Korea, Republic of
Peking University First Hospital

Recruiting

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China (BDTAF)

Chronic Hepatitis B | Chronic Hepatitis C

China
MTmedical Institute of Health
The University of Texas Health Science Center at San Antonio; BioMonde Preparations...

Unknown

4-Methylumbelliferone as a Treatment for Chronic HBV/HCV

Chronic Hepatitis B | Chronic Hepatitis C

United States
R-Pharm
Almedis; Scientific Center EFiS; ChromSystemsLab

Completed

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis c Genotype 1

Russian Federation
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Chronic Hepatitis C Virus

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
Toray Industries, Inc

Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Japan
Merck Sharp & Dohme LLC

Completed

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Chronic Hepatitis C (HCV)
University Health Network, Toronto

Terminated

Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Chronic Hepatitis C - Genotype 3

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC

Completed

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Chronic Hepatitis C Virus
Vertex Pharmaceuticals Incorporated

Completed

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
Shanghai Zhimeng Biopharma, Inc.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B

Chronic Hepatitis b
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase (PILOT)

Chronic Hepatitis b

China
Fujian Akeylink Biotechnology Co., Ltd.

Recruiting

Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets

Chronic Hepatitis b

China
Nguyen Thi Trieu, MD

Approved for marketing

Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B (HBV)

CHRONIC HEPATITIS B

Vietnam
Tarek Hassanein
Shanghai Sundise Traditional Chinese Medicine Co., Ltd.

Completed

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Chronic Hepatitis C Infection

United States
ViiV Healthcare

Completed

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

CHRONIC HEPATITIS B

Iran, Islamic Republic of
Qilu Pharmaceutical Co., Ltd.

Unknown

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b

Chronic Hepatitis b

China
Assiut University

Unknown

Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents

Chronic Hepatitis c
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA (QL-007)

Chronic Hepatitis b

China
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients

Chronic Hepatitis b

New Zealand
Beijing Ditan Hospital

Unknown

The Changes of Cytokines During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Treg Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
National Taiwan University Hospital
Chiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaborators

Recruiting

Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue (CHANGE)

Chronic Hepatitis b | Hepatitis B Reactivation

Taiwan
Mahidol University

Unknown

HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg

Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine

Thailand
Ly Hoa Anh Minh

Recruiting

Impact of Hepatitis B Virus Genotype on Treatment Response in Children With Chronic Hepatitis B

Chronic Hepatitis b

Vietnam
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Sanuo Jiayi Biotechnology Co. LTD

Terminated

Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Chronic Hepatitis b

China
GeneCure Biotechnologies

Recruiting

Therapeutic Hepatitis C Virus Vaccine

Chronic Hepatitis C Infection

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection

3

Subscribe